Silexion Therapeutics Corp has announced a significant corporate action: a 1-for-24 reverse share split of its ordinary shares. This move is designed to help the company regain compliance with Nasdaq's minimum bid price requirement and enhance its market position as it continues its clinical development efforts. The reverse share split will take effect after the market closes on November 10, 2026, with trading on a split-adjusted basis beginning on November 11, 2026.
Founded as a clinical-stage biotechnology company, Silexion specializes in RNA interference therapies targeting KRAS-driven cancers. The company is currently advancing its lead product candidate, SIL204, through a Phase 2/3 clinical trial for treating locally advanced pancreatic cancer. This reverse share split is a strategic step to strengthen its financial standing and support ongoing clinical initiatives.
According to the SEC filing dated November 9, 2026, shareholders approved this reverse share split during a meeting on October 26, 2026. The company aims to improve its capital structure and remedy outstanding deficiencies related to its Nasdaq listing. The par value of the shares will increase from $0.135 to $3.24 as a result of this action, and no fractional shares will be issued.
"This reverse share split is a deliberate step to preserve our Nasdaq listing and reinforce the capital structure that supports Silexion’s clinical execution," stated Ilan Hadar, Chairman and CEO of Silexion. He emphasized that the higher per-share trading price should help remedy the Nasdaq bid price deficiency and broaden the universe of investors engaging with the company.
The reverse share split will automatically adjust the number of shares held by shareholders without requiring any action on their part. Shareholders holding shares in book-entry form will see their shares adjusted automatically, while those with brokers will have their accounts updated accordingly.
Silexion's decision to implement a reverse share split reflects broader trends in the biotechnology industry, where companies often take similar actions to maintain compliance with listing requirements and enhance their market appeal. The company’s focus on innovative treatments for solid tumor cancers positions it well to capitalize on future growth opportunities.
As Silexion moves forward with its clinical trials and strategic initiatives, the reverse share split is expected to play a crucial role in its efforts to attract new investors and secure additional funding for its innovative therapies.
For more information about Silexion Therapeutics and its product candidates, visit silexion.com.
Read Next
Cloudflare's Michelle Zatlyn Sells Over $1.5M in Shares
Zurn Elkay VP LaMotte Jeremy L Reports Stock Sale
XTI Aerospace CEO Jeremy Schneiderman Reports Stock Exchange
Jennifer Salinas acquires 366,529 shares in Cerence Inc.
Mentz Christian acquires 125,979 shares of Cerence Inc.
Cerence CEO Acquires 819,039 Shares in Stock Transaction










